StonvexLoading…
StonvexStonvexStonvexCore line items from AORT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $116.34M | $441.33M | $325.34M | $211.95M |
Operating Income | $5.79M | $33.74M | $23.07M | $10.53M |
Net Income | $1.42M | $9.77M | $7.34M | $840.00K |
EPS (Diluted) | $0.03 | $0.21 | $0.16 | $0.02 |
Total Assets | $883.16M | $884.80M | $857.66M | $838.39M |
Total Liabilities | $432.69M | $436.56M | $418.97M | $418.49M |
Cash & Equivalents | $55.76M | $64.91M | $73.43M | $53.48M |
Free Cash Flow OCF − CapEx | $-6.85M | $839.00K | $8.79M | $-8.87M |
Shares Outstanding | 49.73M | 47.16M | 45.99M | 44.50M |